Intraventricular fibrinolysis for severe aneurysmal intraventricular hemorrhage: a randomized controlled trial and meta-analysis
- 702 Downloads
The aim of this study was to assess the safety and efficacy of intraventricular fibrinolysis (IVF) for aneurysmal subarachnoid hemorrhage (aSAH) with severe intraventricular hemorrhage (IVH). In this randomized controlled trial, between 2005 and 2009, patients with aSAH and severe IVH were randomly assigned into two groups: one treated with external ventricular drainage (EVD) combined with intraventricular recombinant tissue plasminogen activator (rt-PA) and the second with EVD alone. The primary end-point was mortality rate within the first 30 days. We performed meta-analysis including all published articles that compared IVF + EVD to EVD alone in patients with aSAH IVH. Eleven patients were included in the rt-PA group, eight in the control group. At 30 days, mortality rate was lower in the rt-PA group (45.5 vs. 62.5 %), but results were not statistically significant (p = 0.65). Clearance of third and fourth ventricles was obtained previously in the rt-PA group (4.25 days) compared to the control group (10.67 days) (p = 0.001). There was no statistically significant difference concerning the occurrence of complications. The meta-analysis showed a better survival rate with IVF without raised statistical significance (odds ratio = 0.32 [95 % confidence interval, 0.10–1.03]). This study shows that IVF is as safe as EVD alone for aSAH with severe IVH. It accelerates blood clot resolution in the ventricular system. Mortality rate could be improved by IVF but without significant results. Because of the severity and rarity of this pathology, a multicenter study is required.
Clinical Trial Registration Information: www.clinicaltrials.gov (NCT00823485)
KeywordsIntraventricular hemorrhage Subarachnoid hemorrhage Tissue plasminogen activator Fibrinolytic agents Randomized controlled trial Meta-analysis
We wish to express our gratitude to Dr. Laligam N. Sekhar from the University of Washington Medical Center, Seattle, USA, for his prompt response to our data request. This trial was financed by the Institutional Review Board of the Nice Hospital University, France.
Conflict of interest
The authors report no conflicts of interest concerning the materials or methods used in this study or the findings specified in this paper.
- 2.Ducruet AF, Hickman ZL, Zacharia BE, Grobelny BT, Narula R, Guo KH, Claassen J, Lee K, Badjatia N, Mayer SA, Connolly ES Jr (2010) Exacerbation of perihematomal edema and sterile meningitis with intraventricular administration of tissue plasminogen activator in patients with intracerebral hemorrhage. Neurosurgery 66(4):648–655. doi: 10.1227/01.NEU.0000360374.59435.60 PubMedCrossRefGoogle Scholar
- 11.Naff N, Williams MA, Keyl PM, Tuhrim S, Bullock MR, Mayer SA, Coplin W, Narayan R, Haines S, Cruz-Flores S, Zuccarello M, Brock D, Awad I, Ziai WC, Marmarou A, Rhoney D, McBee N, Lane K, Hanley DF Jr (2011) Low-dose recombinant tissue-type plasminogen activator enhances clot resolution in brain hemorrhage: the intraventricular hemorrhage thrombolysis trial. Stroke 42(11):3009–3016. doi: 10.1161/STROKEAHA.110.610949 PubMedCrossRefGoogle Scholar
- 12.Naff NJ, Hanley DF, Keyl PM, Tuhrim S, Kraut M, Bederson J, Bullock R, Mayer SA, Schmutzhard E (2004) Intraventricular thrombolysis speeds blood clot resolution: results of a pilot, prospective, randomized, double-blind, controlled trial. Neurosurgery 54(3):577–583, discussion 583–574PubMedCrossRefGoogle Scholar
- 16.Ramakrishna R, Sekhar LN, Ramanathan D, Temkin N, Hallam D, Ghodke BV, Kim LJ (2010) Intraventricular tissue plasminogen activator for the prevention of vasospasm and hydrocephalus after aneurysmal subarachnoid hemorrhage. Neurosurgery 67(1):110–117. doi: 10.1227/01.NEU.0000370920.44359.91, discussion 117PubMedCrossRefGoogle Scholar
- 18.Rosen DS, Macdonald RL, Huo D, Goldenberg FD, Novakovic RL, Frank JI, Rosengart AJ (2007) Intraventricular hemorrhage from ruptured aneurysm: clinical characteristics, complications, and outcomes in a large, prospective, multicenter study population. J Neurosurg 107(2):261–265. doi: 10.3171/JNS-07/08/0261 PubMedCrossRefGoogle Scholar
- 19.S.F.A.R. (2004) Hémorragie sous-arachnoidienne grave. Conférence d'experts. Société Française d'Anesthésie et de Réanimation, ParisGoogle Scholar
- 25.Varelas PN, Rickert KL, Cusick J, Hacein-Bey L, Sinson G, Torbey M, Spanaki M, Gennarelli TA (2005) Intraventricular hemorrhage after aneurysmal subarachnoid hemorrhage: pilot study of treatment with intraventricular tissue plasminogen activator. Neurosurgery 56(2):205–213, discussion 205–213PubMedCrossRefGoogle Scholar
- 26.Webb AJ, Ullman NL, Mann S, Muschelli J, Awad IA, Hanley DF (2012) Resolution of intraventricular hemorrhage varies by ventricular region and dose of intraventricular thrombolytic: The Clot Lysis: Evaluating Accelerated Resolution of IVH (CLEAR IVH) Program. Stroke. doi: 10.1161/STROKEAHA.112.650523 Google Scholar